PRSS42P

Across TCGA pan-cancer cohorts, PRSS42P Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRSS42P data layer compared with 22 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PRSS42P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRSS42P expression acts as an unfavorable survival marker.

BLCA, SARC, and ESCA are the cancer types where PRSS42P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.051	0.684	<.001	24	view →
SARC	DFS	Median	All	0.107	0.613	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
LIHC	DFS	Median	All	0.043	0.543	<.001	6	view →
SKCM	OS	Median	All	0.299	0.781	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRSS42P–BLCA (OS)

Open the BLCA breakdown →